Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimatoprost, Microneedling, and Excimer Laser for Vitiligo
NCT04738149Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bimatoprost in Vitiligo (2 arms), sponsored by Medical University of South Carolina. Primary endpoints: Percentage of skin repigmentation at 12 weeks and Number of patients with perceived improvement at 12 weeks. Started Nov 2021; status: completed.
02
Drugs
bimatoprost
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT04738149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04738149.